Roivant to sell Dermavant unit to Organon for up to $1.2 billion in cash and royalties
Roivant's subsidiary Dermavant agreed on September 17, 2024 to be acquired by Organon for up to about $1.2 billion, including a $175 million payment at closing, a $75 million milestone on FDA approval of VTAMA for atopic dermatitis, and up to $950 million in sales-based milestones, plus tiered royalties. Roivant owns about 87% of Dermavant's shares, so the deal would deliver most of the proceeds to Roivant, though the amount depends on future milestones and the closing is subject to conditions.
Key points
- Organon agreed to acquire Dermavant for up to about $1.2 billion in aggregate cash consideration, including a $175 million payment at closing
- Additional $75 million payable on FDA approval of VTAMA for atopic dermatitis, and up to $950 million in tiered net sales milestones
- Roivant owns approximately 87% of Dermavant's common and preference shares; shareholder written consent of at least 75% of voting rights was obtained
- Expected to close in the fourth quarter of 2024; either party may terminate if not closed by March 17, 2025
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 23, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.